NEW YORK – 280Bio on Friday said it began treating patients with advanced cancers harboring KRAS, HRAS, or NRAS mutations in a Phase I trial of its pan-RAS inhibitor TEB-17231.
Researchers will enroll up to 60 patients in the trial with unresectable or metastatic advanced solid tumors to evaluate TEB-17231, also called YL-17231. Previous preclinical research has suggested that TEB-17231 could overcome resistance to KRAS G12C inhibitors.
280Bio, headquartered in South San Francisco, California, is developing TEB-17231 in partnership with MD Anderson Cancer Center and its Shanghai-based parent company Yingli Pharma. The first patient in this trial was enrolled at MD Anderson.
280Bio is also evaluating linpersilib — a PI3Kδ inhibitor that became commercially available in China in 2022 — in a T-cell lymphoma Phase II trial, and the TGFβR1 inhibitor YL-13027 in a Phase I dose escalation study in solid tumors.